Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in different molecular types of breast cancer

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1757-1764

  Raica, Marius ^a   Cimpean, Anca Maria ^a   Ceausu, Raluca ^a   Ribatti, Domenico ^b  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Breast cancer; Lymphatic microvessel density; Molecular classification; VEGF C; VEGFR 3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY D2-40; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC MICROVESSEL DENSITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MICROVESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79958157083     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Smith BD, Smith GL, Hurria A, Hortobagyi GN and Buchholtz TA: Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27: 2758-2765, 2009.
2. Dawson PJ, Ferguson DJ and Karrison T: The pathologic findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer 50: 2131-2138, 1982. (Pubitemid 13203620)
3. Page DL: Prognosis and breast cancer. Recognition of lethal and favourable prognostic types. Am J Surg Pathol 15: 334-349, 1991.
4. Hugh J, Hanson J, Cheang MCU, Nielsen TO and Perou CM: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27: 1168-1176, 2009.
5. Pakkiri P, Lakhani SR and Smart CE: Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology 41: 89-99, 2009.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 96: 10869-10674, 2001.
7. Reis-Filho JS and Tutt ANJ: Triple negative tumours: a critical review. Histopathology 52: 108-118, 2008. (Pubitemid 350265179)
8. Spitale A, Mazzolla P, Soldini D, Mazzucchelli L and Bordoni A: Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20: 628-635, 2009.
9. Carey LA, Dees CE, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007. (Pubitemid 46698581)
10. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN and Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005. (Pubitemid 41170290)
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004. (Pubitemid 39100473)
13. Morris SR and Carey LA: Molecular profiling in breast cancer. Rev Endocr Metab Disord 8: 185-198, 2007. (Pubitemid 47524869)
14. Hsieh S-H, Look MP, Sieuwerts AM, Foekens JA and Hunter KW: Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res 11: R75, 2009.
15. Gu Y, Qi X and Guo S: Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis 25: 717-725, 2008.
16. Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K: Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 91: 125-132, 2005.
17. Mylona E, Alexandrou P, Mpakali A, Giannopoulou I, Liapis G, Markaki S, Keramopoulos A and Makopoulou L: Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol 33: 294-300, 2007. (Pubitemid 46508645)
18. Gisterek I, Matkowski R, Kozlak J, Dus D, Szelakowska J and Komafel J: Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer - 10 years follow-up analysis. Anticancer Res 27: 2797-2802, 2007. (Pubitemid 47228000)
19. Bando H, Welch HA, Horiguchi S, Funata N, Ogawa T and Toi M: The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncol Rep 15: 653-659, 2006.
20. Lee SK, Cho EY, Kim WW, Hur SM, Kim S, Choe J-H, Kim J-H, Kim JS, Lee JE, Nam SJ and Yang J-H: The prediction of lymph node metastasis in ductal carcinoma in situ with microinvasion by assessing lymphangiogenesis. J Surg Oncol 102: 225-229, 2010.
21. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G and Weil RJ: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30: 1097-1104, 2006. (Pubitemid 44299342)
22. Liu HT, Ma R, Yang QF, Du G and Zhang CJ: Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. Int J Surg Pathol 17: 426-431, 2009.
23. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
24. Allred DC, Harvey JM, Berardo M and Clark GH: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998. (Pubitemid 28144151)
25. Choi WWL, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C and Young AN: Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18: 143-152, 2005. (Pubitemid 40128107)
26. Ran S, Volk L, Hall K and Flister MJ: Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17: 229-251, 2010.
27. Nakamura Y, Yasouka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakugo K: Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16: 309-314, 2003. (Pubitemid 36443979)
28. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes I, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001. (Pubitemid 32148486)
29. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376, 2008. (Pubitemid 351413917)
30. Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Sawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B and Perou CM: A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 98: 1327-1335, 2008. (Pubitemid 351543585)
31. Hoar FJ, Chaudhri S, Wadley MS and Stonelake PS: Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. Eur J Cancer 39: 1698-1703, 2003.
32. Schoppmann SF, Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R and Birner P: HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol 21: 955-960, 2009.
33. Wülfing P, Kersting C, Buerger H, Mattsson B, Mesters R, Gustmann C, Hinrichs B, Tio J, Böcker W and Kiesel L: Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92: 1720-1728, 2005. (Pubitemid 40756484)
34. Timoshenko AV, Rastogi S and Lala PK: Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 97: 1090-1098, 2007. (Pubitemid 47587011)
35. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B and Skobe M: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66: 2650-2657, 2006.
36. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC and Swartz MA: Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 97: 14-21, 2005.
37. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD and Ran S: Anti-VEGF-A therapy reduces lymphatic density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 121: 2181-2191, 2007. (Pubitemid 47585596)